Outcome of Metastatic Colorectal Cancer: Analysis of a Consecutive Series of 229 Patients. The Impact of a Multidisciplinary Approach
- 1 October 2006
- journal article
- Published by Wolters Kluwer Health in Diseases of the Colon & Rectum
- Vol. 49 (10) , 1596-1601
Abstract
New chemotherapy agents and integrated treatments have improved the prognosis of patients with metastatic colorectal cancer. From January 2000 to December 2002, 229 consecutive metastatic patients were prospectively followed and their outcomes were analyzed. They were divided initially into four treatment groups: A, palliative chemotherapy for extensive extrahepatic disease with or without hepatic disease (97 patients); B, palliative chemotherapy as in Group A for extensive hepatic disease unlikely to become resectable (36 patients); C, neoadjuvant chemotherapy for potentially resectable liver metastases if responsive to therapy (33 patients); D, immediate surgery for liver metastases (63 patients). The series was analyzed after a median follow-up of 22.6 months. The median progression-free survival was 9, 7.3, 11.5, and 26 months in Groups A, B, C, and D, respectively. The median overall survival was 20.1, 17.2, 24.8, and >48 months in Groups A, B, C, and D, respectively. The outcome was considered for the 69 patients with metastases confined to the liver (Groups B and C), who were treated initially with chemotherapy. Surgery was performed in 21 patients (5 from Group B, and 16 from Group C) and was R0 in 16. In resected patients, the median progression-free survival was 14.7 months and the median overall survival was 40.5 months. In unresected patients, the median progression-free survival was 7.6 months and the median overall survival was 17.5 months. Neoadjuvant therapy may prolong overall survival in a subset of patients with multiple hepatic metastases. The global impact on progression-free survival is low; less than one-half of the patients resected after chemotherapy are disease-free at three years. However, patients resected after chemotherapy obtained overall survival similar to that of primary surgery, suggesting a positive role for integrated approaches.Keywords
This publication has 20 references indexed in Scilit:
- N9741: FOLFOX (oxaliplatin(Oxal)/ 5-fluorouracil (5-FU)/ leucovorin (LV) or reduced dose R-IFL (CPT-11 + 5-FU/LV) in advanced colorectal cancer (CRC): Final efficacy data from an intergroup studyJournal of Clinical Oncology, 2004
- FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR StudyJournal of Clinical Oncology, 2004
- Chemotherapy and surgery: new perspectives on the treatment of unresectable liver metastasesAnnals of Oncology, 2003
- Management of colorectal liver metastasesColorectal Disease, 2003
- Liver Metastases From Colorectal Cancer: The Turning PointJournal of Clinical Oncology, 2002
- Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal CancerNew England Journal of Medicine, 2000
- Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trialThe Lancet, 2000
- Clinical Score for Predicting Recurrence After Hepatic Resection for Metastatic Colorectal CancerAnnals of Surgery, 1999
- Liver Resection for Metastatic Colorectal Cancer: Assessing the Risk of Occult Irresectable DiseaseJournal of the American College of Surgeons, 1999
- Surgical resection of colorectal carcinoma metastases to the liver: A prognostic scoring system to improve case selection, based on 1568 patientsCancer, 1996